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Abstract. Temporomandibular joint dysfunction (TMD) is 
a collection of clinical symptoms that involve masticatory 
muscles and the temporomandibular joint (TMJ). Common 
symptoms include limited jaw motion and joint sound/pain, 
along with TMJ disc displacement. TMD is frequently associ-
ated with synovitis, a chronic inflammation of the synovium. 
Fibroblast‑like synovial cells have been identified to produce 
several inflammatory mediators and may have an important 
role in the progression of TMJ inflammation. Degradation 
of the extracellular matrix molecule elastin may lead to the 
release of bioactive peptides. The present study aimed to 
explore the role of elastin-derived peptides (EDPs) in human 
temporomandibular disorders. Therefore, interleukin-6 (IL-6) 
expression in the synovial fluid obtained from patients with 
TMD correlated significantly with two clinical parameters, 
specifically TMJ locking and pain/jaw function on a visual 
analog scale (VAS). To the best of our knowledge, this is the 
first study to determine that the concentration of EDPs in 
synovial fluid from patients with TMD may also be signifi-
cantly correlated with the duration of TMJ locking, the VAS 
score and IL-6 expression. In vitro, EDPs act on human 
TMJ synovial cells to promote upregulation of IL-6 and 
the elastin-degrading enzyme matrix metalloproteinase-12 
(MMP-12). The upregulation of IL-6 and MMP-12 expression 
by EDPs may be mediated through elastin-binding proteins 
(EBP) and a protein kinase A signalling cascade. These find-
ings suggest a model for inflammation in the TMJ where 
EDPs are generated by harmful mechanical stimuli, induce 
both a pro‑inflammatory cascade and increase expression of 
MMP-12 through activation of the EBP signalling cascade. 
This may lead to further increases in EDP levels, establishing 
a positive feedback loop leading to chronic inflammation in 
the TMJ. Therefore, significantly elevated levels of EDPs and 
IL‑6 in the synovial fluid of the TMJ may be indicators of the 
pathological conditions of the joint.
Introduction
Temporomandibular joint dysfunction (TMD) is a collective 
term describing a range of clinical symptoms that involve 
the muscles of mastication and the temporomandibular joint 
(TMJ), which is a bilateral synovial joint formed from the 
upper temporal bone of the skull and lower jawbone (mandible). 
TMD is characterized by restricted jaw motion and joint sound 
and pain and often includes TMJ disc displacement, internal 
derangement, and osteoarthritis (OA). In TMD, synovitis 
that often accompanies intra-capsular pathologic conditions 
is characterized by chronic inflammatory changes (1‑3). The 
synovial membrane that covers the inner wall of the TMJ 
capsule is populated by fibroblast-like stromal cells and 
lining cells. Fibroblast-like cells have an important role in the 
progression of inflammation in the TMJ due to their ability to 
produce a number of pro‑inflammatory mediators (4‑6). The 
process by which TMJ synovitis is initiated and maintained 
remains to be elucidated; however, several pro‑inflammatory 
cytokines, such as tumour necrosis factor (TNF-α), interleukin 
(IL)-1β, IL-6, IL-8 and interferon γ (IFNγ) have been detected 
in either synovial fluid (7‑13) or in synovial tissue (5) obtained 
from patients with internal derangement of the TMJ or OA of 
the TMJ. Therefore, these cytokines may be involved in the 
pathophysiology of TMJ internal derangement and OA.
Elastin is an extracellular matrix molecule responsible for 
the mechanical resilience of tissues and was initially believed 
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to be restricted to this role (14). In keeping with its important 
structural role, elastin has a very long half-life. However, 
elastin turnover is dramatically accelerated in various disease 
states including arthritis, atherosclerosis, emphysema and 
cancer (15). Elastin degradation leads to the production of 
bioactive peptides termed elastin-derived peptides (EDPs) (16). 
The hexapeptide VGVAPG, which may be detected in insoluble 
elastin and EDPs, may responsible for bioactivity as it may bind 
to the elastin receptor and exert numerous biological effects, 
including atherosclerosis (17). Although several other recep-
tors have been suggested to bind EDPs (αvβ3 and αvβ5 integrins, 
galectin-3), the principal EDPs receptor remains the elastin 
receptor complex (18). This heterotrimer is composed of a 
peripheral subunit, termed the elastin binding protein (EBP), 
associated with the protective protein/cathepsin A. The latter 
is bound to a membrane-associated protein termed neuramini-
dase‑1. Specific interactions between inflammatory cells and 
EDPs previously established (19).
Anatomically, the TMJ disc is attached to the capsule and 
its surrounding structures (20). In humans TMJ disc elastin is 
abundant in both the anterior and posterior attachment struc-
tures, particularly thick elastic fibres are located in the upper 
bilaminar zone (21). It is of note that, as a consequence of 
aging, there is a reduction in the number of elastic fibres in the 
TMJ disc (22-24). However, the absence of mastication move-
ments in foetuses and new-borns correlates with the presence 
of abundant elastic fibres in all areas of the TMJ disc (24). In 
adults with teeth, as well as edentulous older people, elastic 
fibre density has been identified to be considerably reduced 
in the middle of the bilaminar intermediate zone (25). It is 
likely that mechanical factors, particularly pressure created 
during mastication, may explain this phenomenon. Previous 
studies on diseased human TMJ discs have revealed a signifi-
cant reduction in the number of elastic fibres in the bilaminar 
zone (23,26,27).
At present, there is minimal information regarding the 
involvement of elastin degradation in the processes of syno-
vitis in human TMD. The present study aimed to investigate 
the importance of EDPs in human TMD. To the best of our 
knowledge, the present study was the first to reveal that EDPs 
in synovial fluid of patients with TMD were correlated with 
the duration of TMJ locking and VAS score, and that EDPs 
induce inflammatory responses in human TMJ synovial cells. 
This important finding indicates that elastin degradation is 
an event that may be involved in the establishment of human 
TMD.
Materials and methods
Human samples. Experiments using human samples were 
approved by the Ethics Committee of the Kanazawa University 
Graduate School of Medical Science (IRB no. 2014-005, 
351-2), and written informed consent was obtained from 
patients providing the specimens. Patients were diagnosed 
with closed lock disc disease in the temporomandibular joint 
and were treated using pumping manipulation at Kanazawa 
University Hospital (Kanazawa, Japan) between April 1997 
and March 2000. Synovial fluid was obtained from the TMJ 
of 28 patients. The patients ranged between 16 and 66 years of 
age (38.3±17.7 years old, mean ± SD), and 25 patients (89%) 
were female. Samples were collected from the TMJ using a 
push and pull technique, as previously described (28). Clinical 
examinations were performed prior to synovial fluid collec-
tion. They included recordings of maximum incisal opening, 
pain upon incisal opening, pain upon palpation of muscles 
and the TMJ, subjective reports on pain and function of the 
jaw, using a visual analogue scale (VAS), and the duration of 
locking disc disease.
Cell culture. Human synovial fibroblast cells were prepared 
from TMJ synovial tissues obtained at arthroplasty from 
1 patient with TMJ ankyloses (68 years old male) and 
2 patients with condylar fracture of the mandible (23-year-old 
female and 43-year-old male). These 3 patients underwent 
surgery at Kanazawa University Hospital between April 1997 
and March 2000. Tissue samples were treated with 5% 
bacterial collagenase type I (Worthington Biochemical 
Corporation, Freehold, NJ, USA) for 1 h at 37˚C and 0.02% 
trypsin (Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
for 30 min at 37˚C. After the activities of these proteinases 
were blocked with 10% foetal bovine serum (FBS; GE 
Healthcare, Logan, UT, USA), the 1x105 cells were seeded 
in culture dishes and maintained in Dulbecco's modified 
Eagle's medium (DMEM; Sigma-Aldrich; Merck Millipore, 
Darmstadt, Germany) containing 10% FBS at 37˚C in a 
humidified 5% CO2 atmosphere. Human lung elastin peptides 
were purchased from Elastin Products Company (Owensville, 
MO, USA) (29). Cells below passages 3-6 were used in the 
subsequent experiments. Prior to EDP treatment, cells were 
pre‑incubated at 37˚C for 12 h in serum‑free DMEM medium 
and then incubated at 37˚C for 24 h in DMEM containing 
2% FBS and EDP (Elastin Products Company) at various 
concentrations (0, 25, and 50 µg/ml). For the in vitro inhibi-
tion studies, cells were pre-incubated for 12 h in serum-free 
DMEM medium with or without the protein kinase A (PKA) 
inhibitor N-[2-((p-bromocinnamyl) amino)ethyl]-5-isoquino-
linesulfonamide (H89; 2 µM; LKT Laboratories, Inc., St. Paul, 
MN, USA) or β-lactose (20 mM; Santa Cruz Biotechnology, 
Inc., Dallas, TX, USA) or vehicle control (PBS only), and then 
incubated at 37˚C for 24 h in DMEM containing 2% FBS and 
with or without 50 µg/ml EDPs.
Enzyme‑linked immunosorbent assay (ELISA). Human TMJ 
synovial fluid and supernatants, following 5 min centrifugation 
at 12,500 x g and 4˚C, obtained from cultured primary TMJ 
synovial cells were analysed for the presence of EDPs, IL-1β, 
IL-6, TNF-α and matrix metalloproteinase-12 (MMP-12) 
using the appropriate ELISA kit (EDPs, cat. no. SK00806-01; 
Aviscera Bioscience Inc., Santa Clara, CA, USA; IL-1β, cat. 
no. DLB50; IL-6, cat. no. D6050; TNF‑α, cat. no. DTA00C; all 
from R&D Systems, Inc., Minneapolis, MN, USA; MMP-12, 
cat. no. EK0950; Boster Biological Technology, Pleasanton, 
CA, USA) according to the manufacturer's protocols. Total 
protein concentrations in the synovial fluid were determined by 
the dye binding method using an acidic solution of Coomassie 
Brilliant Blue G-250 dye, according to the manufacturer's 
protocol (Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
Values were calculated as pg/mg total protein or ng/mg total 
protein. Data are presented as the mean ± standard error of 
the mean.
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Statistical analysis. For comparisons between samples, data 
was analysed by with analysis of variance and Tukey's multiple 
comparison test using SPSS version 23 (IBM Corporation, 
Armonk, NY, USA). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Concentrations of IL‑1β, IL‑6 and TNF‑α in the synovial fluid 
of patients with TMD are correlated with the duration of TMJ 
disk locking or VAS score. The concentration of IL-1β, IL-6 
and TNF-α in the synovial fluid of patients with TMD was 
quantified using ELISA and the correlation between the levels 
of these proteins and two clinical parameters was determined. 
The duration of TMJ locking had a positive correlation with 
IL-1β (r=0.593; P=0.003; Fig. 1A) and IL-6 levels (r=0.483; 
P=0.016; Fig. 1B); however, no correlation was identified with 
TNF-α levels (r=0.240; P=0.226; Fig. 1C). In contrast, the VAS 
score had a positive correlation with IL-6 (r=0.447; P=0.026; 
Fig. 1D) and TNF-α (r=0.453; P=0.024; Fig. 1E); however, no 
correlation was identified with IL‑1β levels (r=0.164; P=0.407; 
Fig. 1F).
Concentration of EDPs in the synovial fluid of patients with 
TMD and correlation with duration of TMJ disk locking or 
the VAS score. The total concentration of EDPs in the synovial 
Figure 1. IL-1β, IL-6 and TNF-α protein expression in synovial fluid from patients with TMD and their correlation with duration of TMJ disc locking duration 
or VAS score. The duration of TMJ disc locking for each patient was plotted against the respective (A) IL-1β, (B) IL-6 or (C) TNF-α protein levels in synovial 
fluid. The VAS score for each patient was plotted against the respective (D) IL‑1β, (E) IL-6 or (F) TNF-α protein levels in synovial fluid. Each protein level 
represents the mean of three independent experiments. IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; TMD, temporomandibular 
dysfunction; TMJ, temporomandibular joint; VAS, visual analogue scale.
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fluid of patients with TMD was measured and the correlation 
between the EDP levels and the clinical parameters was deter-
mined. The locking duration of TMJ had a positive correlation 
with EDP levels (r=0.750; P=0.0001; Fig. 2A). Similarly, the 
VAS score also had a positive correlation with EDP levels 
(r=0.692; P=0.008; Fig. 2B).
Correlation between EDP levels and IL‑1β, IL‑6 or TNF‑α 
levels in synovial fluid from patients with TMD. The corre-
lation between EDP levels and IL-1β, IL-6 or TNF‑α levels 
in synovial fluid from patients with TMD was determined 
(Fig. 3). EDP levels had a positive correlation with IL-6 
(r=0.527; P=0.009; Fig. 3B); however, no correlation was iden-
tified with IL‑1β (r=0.364; P=0.069; Fig. 3A) or TNF-α levels 
(r=0.101; P=0.609; Fig. 3C).
EDPs stimulate IL‑6 protein production in TMJ human 
synovial fibroblast cells. To determine the role of EDPs 
during the inflammation process in TMD, cultured human 
TMJ synovial fibroblast cells were treated with EDPs at a 
concentration of 0, 25 and 50 and the levels of IL-1β, IL-6 
and TNF-α were measured in the culture media (Fig. 4). 
EDP treatment significantly increased IL-6 protein levels 
compared with the vehicle treated (EDPs 0 µg/ml) cells 
(250.01±5.09 pg/mg at 25 µg/ml; 848.44±34.29 pg/mg at 
50 µg/ml compared to 15.33±9.27 pg/mg for the vehicle control 
group, P<0.05; Fig. 4B). No significant effect was observed on 
IL-1β and TNF‑α protein levels (Fig. 4A and C).
EDPs induce IL‑6 and MMP‑12 expression through EBP. The 
correlation between EDP levels and IL-6 expression observed 
in clinical samples was validated using in vitro inhibition. 
A previous study demonstrated that PKA was a mediator of 
elastin-induced intracellular signalling through EBP (30). 
Therefore, H89, a PKA inhibitor, and β-lactose, another inhibitor 
of EBP mediated signalling (30), was used to determine the role 
of EBP in the stimulation of IL-6 release in response to EDPs 
in TMJ human synovial fibroblast cells. IL‑6 levels treated 
with EDP (777.40±61.99 pg/mg) were significantly inhibited 
by the H89 (345.01±29.29 pg/mg; P<0.05) and β-lactose 
treatments (539.51±30.71 pg/mg; P<0.05; Fig. 5A). EDPs also 
significantly upregulated MMP‑12 expression in the cultured 
synovial fibroblasts (228.47±14.48 pg/mg; P<0.05) compared 
with cells treated with the vehicle control (62.5±3.00 pg/mg; 
Fig. 5B). The upregulation of MMP‑12 was significantly inhib-
ited following treatment with H89 (64.16±3.26 pg/mg; P<0.05) 
and β-lactose (182.22±14.63 pg/mg; P<0.05; Fig. 5B).
Discussion
Previous studies have demonstrated that cytokines 
including IL-1β (9,11,12,31,32), IL-6 (9,11,12,31,33-37) and 
TNF-α (8,11,31,32,34,35) are associated with inflammation 
in synovial joints and loss of the connective tissue in TMJ. 
Therefore, it is possible that increased levels of these cytokines 
may be observed in the synovial fluid of patients with TMD. 
In the present study, IL‑6 expression significantly correlated 
with the two clinical parameters investigated, duration of the 
TMJ disc locking and VAS score. The data of the present study 
was therefore consistent with a previous study which stated 
that IL-6 has a major role in the development of osteoarthritis 
in the TMJ (12). However, in another previous study, levels 
of IL-6 were determined to be comparable in the synovial 
fluids from patients with TMJ and OA, and healthy patients 
with TMJ (32). Previous studies (32,36-38) have revealed a 
negative correlation between frequently isolated cytokines, 
IL-6 (32), TNF-α (37,38) and IL-1β (36,38) and TMD. 
Kaneyama et al (38) suggested that no correlation was observed 
between the IL-1β or TNF-α levels and condyle degenerative 
changes due to the rapid turnover of cytokines within the joint 
cavity (38). However, it is difficult to elucidate the reasons 
behind these controversial findings, and standardization of 
the sampling methods, assay methods and patient cohort will 
be performed in future studies. The present findings may be 
affected by numerous clinical variables, including patient age, 
gender, duration and intensity of TMJ disease. Therefore, in 
the future, carefully designed clinical trials will need to be 
conducted with the aim of using the levels of pro‑inflammatory 
cytokines to predict the extent and severity of TMJ pathology.
The pathophysiology of TMD has been previously investi-
gated and several mechanistic studies have been reported. For 
Figure 2. Concentration of EDPs in synovial fluid from patients with 
TMD and its correlation with duration of TMJ disc locking or VAS score. 
(A) Duration of TMJ disc locking for each patient was plotted against their 
respective EDP expression level in synovial fluid. (B) VAS score for each 
patient was plotted against their respective EDP expression level in synovial 
fluid. Each EDP expression level represents the mean of three independent 
experiments. EDP, elastin-derived peptides; TMD, temporomandibular 
dysfunction; TMJ, temporomandibular joint; VAS, visual analogue scale.
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example, loss of disc elastic fibres was observed following induc-
tion of anterior disc displacement or disc perforation (39,40). 
It has also been reported that the abundance of elastic fibres in 
the bilaminar zone was reduced in patients with internal disc 
derangement (23,26,27). A previous study demonstrated that 
the presence and distribution of newly formed elastic fibres, 
was associated with the degree of disc tissue damage to, or the 
complete absence of collagen bundles (41).
Previous studies (7-13) have focused on examining 
pro-inflammatory cytokines, to the best of our knowledge 
the present study was the first to determine the quantity of 
EDPs present in synovial fluid. In current study determined 
the concentration of EDPs in the synovial fluid of patients with 
TMD and revealed that the levels of EDPs were significantly 
correlated with VAS score or duration of TMJ disc locking as 
well as IL‑6 expression in the synovial fluid of patients with 
Figure 4. EDPs stimulate IL-6 protein expression in TMJ human synovial 
fibroblast cells. Expression of (A) IL‑1β, (B) IL-6 or (C) TNF-α in cultured 
human TMJ synovial fibroblast cells treated with EDPs at 0, 25, and 50 µg/ml 
concentration. Data are presented as the mean ± standard error of the mean 
from triplicate experiments. *P<0.05. EDP, elastin-derived peptides; TMJ, 
temporomandibular joint; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, 
tumor necrosis factor-α.
Figure 3. Concentration of EDPs and the correlation with IL-1β, IL-6 and 
TNF-α levels in synovial fluid from patients with temporomandibular 
dysfunction. Individual patient levels of EDPs in synovial fluid were plotted 
against the patients respective (A) IL-1β, (B) IL-6 or (C) TNF-α protein 
levels in synovial fluid. Each protein level represents the mean of three 
independent experiments. IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, 
tumor necrosis factor-α; EDP, elastin-derived peptides.
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TMD. The biological role of elastin, as the fundamental unit 
of an elastic fibre, was originally believed to be restricted only 
to mechanical maintenance of tissue architecture. This simple 
view of elastin has now evolved as EDPs have been revealed 
to be biologically active in a range of normal and transformed 
cells (42,43). However, despite these new insights, the role 
for EDPs in the pathophysiology of TMD, to the best of our 
knowledge, has not been previously investigated.
In elastin-rich tissues such as arteries, lungs and skin, 
inflammation is concomitant with elastolysis, leading to 
the generation of EDPs (42,44,45). In these cases, a direct 
association between inflammation and EDP levels has been 
established. The present study determined that EDPs may act 
selectively on human TMJ synovial cells to stimulate IL-6 
production, with no significant effect on IL-1β or TNF‑α 
production. IL‑6 is produced at the site of inflammation and 
has a key role in the acute phase response (46). Following 
the onset of the inflammatory response, IL-6 secreted by 
synovial cells in the TMJ may act as a chemoattractant for 
other cell types important to tissue degradation. In a previous 
study, stimulation of cartilage explants with IL-6 potentiated 
proteoglycan (aggrecan) catabolism in articular cartilage. This 
catabolism was associated with aggrecanase activity (47). In 
this regard, upregulation of IL-6 is critical for the progression 
of arthritic diseases. Under inflammatory conditions, changes 
in the levels of polarized Th1 and Th2 cells may also to be 
important (48,49). Therefore, the expression levels of a Th1 
cytokine (TNF-α) and a Th2 cytokine (IL-6) were examined 
in EDP-treated TMJ synovial cells. The expression of IL-6; 
however, not TNF-α, was increased by EDPs suggesting that 
EDPs stimulate a Th2 cellular response. Characterization of 
Th1 and Th2 response has been previously performed using 
synovial tissue samples obtained from a patient with erosive 
rheumatoid arthritis (50). The synovial tissue sample used 
in the present study had an unusual Th2 dominant pattern. 
A previous study has demonstrated that IL‑6 deficient mice 
had reduced Th2 responses and increased arthritis (51). These 
findings demonstrated that a predominantly Th2 response may 
be associated with arthritis.
EDPs may act via EBP, which is located on the membrane of 
fibroblasts, granulocytes, lymphocytes, monocytes and cancer 
cells (52). H89 inhibition of PKA was used to determine the role 
of PKA as a key intracellular signalling mediator downstream 
of EBP (30). EBP is inhibited by β-lactose (30); however, 
α-lactose is only a partial inhibitor due to its partial conversion 
to β-lactose by anomerization (53). The present study revealed 
that H89 and β-lactose inhibited EDP stimulated expression 
of IL‑6 in TMJ synovial cells. These findings suggest that 
the induction of IL-6 expression by EDPs involved the EBP 
and a PKA signalling cascades. MMP-12 is a member of a 
group of enzymes that are able to degrade elastin. The present 
study revealed that MMP-12 is secreted from EDP-treated 
TMJ synovial cells and that, similarly to IL-6, this process 
was also inhibited by H89 and β-lactose. Therefore, from these 
findings a model for the initiation of the inflammatory process 
in the TMJ may be proposed. Harmful mechanical stimuli, 
and in particular pressure, may lead to tissue damage in the 
TMJ. EDPs are then generated, as endogenous danger signals 
and induce a pro‑inflammatory cascade by activating EBP 
signalling. Subsequently, pro‑inflammatory mediators, such as 
IL-6 and MMP-12 are upregulated and trigger further tissue 
damage leading to increased EDP levels. Therefore, a positive 
feedback loop is established and may lead to chronic inflam-
mation of the TMJ. Therefore, significantly higher levels of a 
combination of EDPs and IL‑6 in the synovial fluid of patients 
with TMJ may be indicators of the pathological condition of 
the joint.
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Figure 5. EDPs induce IL-6 and MMP-12 expression through elastin binding 
protein. Expression levels of (A) IL-6 and (B) MMP-12 in cultured human 
temporomandibular joint synovial fibroblast cells treated with EDPs alone or 
EDPs in the presence of H89, β-lactose, or vehicle control. Data are presented 
as the mean ± standard error of the mean from triplicate experiments. 
*P<0.05. EDP, elastin-derived peptides; IL-6, interleukin-6; MMP-12, matrix 
metalloproteinase 12; H89, protein kinase A inhibitor.
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